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Epstein-Barr virus (EBV) establishes life-long latent infections in normal human B cells and is closely associated with posttransplant lymphoproliferative disorder (PTLD) and endemic Burkitt lymphoma (BL) (Rickinson & Kieff, 2007) . PTLD and its in vitro experimental model, lymphoblastoid cell line (LCL), are associated with the most immunogenic form of latency (latency III) in which all EBV nuclear antigens (EBNA-1, -2, -LP, -3A, -3B and -3C) and latent membrane proteins (LMP-1, -2A and -2B) are expressed. Endemic BL can display either type I or Wp-restricted (c. 15% of the endemic BL) latency (Kelly et al, 2013) . In type I latency, only EBNA-1 is expressed. In Wp-restricted latency, EBNA-1, EBNA-LP, EBNA-3A, EBNA-3B and EBNA-3C are expressed (Rowe et al, 2009) . BL cell lines can also switch to express latency III infection after long periods of in vitro culture (Gregory et al, 1990) .
Most of the EBV latent proteins expressed in Wp-restricted or type III latency were shown to be oncogenic and might contribute to the resistance of EBV-associated lymphomas to standard chemotherapy. Leao et al (2007) showed that EBV-positive BL cells of type III latency were more resistant to the killing by nocodazole or taxol in comparison to EBVnegative or latency I BL cells. Kelly et al (2005) showed that Wp-restricted BL cells were also more resistant to the treatment with ionomycin or anti-IgM when compared with latency I BL cells. Another study found that EBV conferred essential anti-apoptotic effects on both Wp-restricted BL and PTLD cells but not on latency I BL cells (Vereide & Sugden, 2011) . EBNA-LP, -3A, -3B and -3C are expressed in both Wp-restricted and type III latency but not in type I latency (Rickinson & Kieff, 2007) . Among these viral latent proteins, EBNA-3A and EBNA-3C were shown to have anti-apoptotic functions in different B-cell malignancies. Tumour suppressor genes, such as BCL2L11 (Bim), CDKN2A (p16 INK4A ) and CDKN1A (p21
WAF1
) are downregulated by EBNA-3A or -3C through epigenetic modification of the host cell genomes (Cooper et al, 2003; Maruo et al, 2006 Maruo et al, , 2011 Anderton et al, 2008; Hertle et al, 2009; Paschos et al, 2009; Skalska et al, 2010; Saha et al, 2011) . The epigenetic modification by the virus latent proteins could be achieved either through interaction with C-terminal binding protein or direct recruitment of histone deacetylases (HDAC) such as HDAC1 and HDAC2 (Radkov et al, 1999; Chinnadurai, 2002; Knight et al, 2003; White et al, 2010) .
Histone deacetylase inhibitors can inhibit various types of HDAC enzymes and mediate potent anti-cancer effects in a wide range of malignancies. We have reported that an US Food and Drug Administration (FDA)-approved HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), can induce growth arrest and apoptosis of EBV-positive gastric carcinoma and nasopharyngeal carcinoma cells by disrupting the EBV latency (Hui & Chiang, 2010; Hui et al, 2012) . HDAC inhibitors can also induce the expression of BCL2L11, CDKN2A and CDKN1A (Gui et al, 2004; Zhou et al, 2009 ). The induction of apoptosis and up-regulation of tumour suppressor genes by HDAC inhibitors can be greatly enhanced when co-administered with proteasome inhibitors, such as bortezomib (Yu et al, 2003; Pei et al, 2004; Emanuele et al, 2007; Heider et al, 2009; Hui & Chiang, 2014) . However, it remains unknown whether combination of HDAC and proteasome inhibitors can affect the expression of tumour suppressor genes and induce apoptosis of EBV-associated B-cell malignancies.
In this study, we tested the hypothesis that a combination of HDAC inhibitors (e.g. SAHA) and proteasome inhibitors (e.g. bortezomib) can synergistically induce apoptosis of Wp-restricted BL and LCLs. Our results showed that SAHA/ bortezomib can preferentially induce the killing of Wprestricted and latency III BL cells but not latency I BL cells. The synergistic killing can also be achieved in EBV-transformed LCLs that express type III latency. The synergism of SAHA/bortezomib is probably mediated through reversal of the suppressive effects of EBNA-3 proteins on CDKN2A and CDKN1A, with subsequent induction of apoptosis in the Wp-restricted BL and LCLs. Furthermore, this drug combination suppressed the growth of Wp-restricted BL xenografts in vivo. Our findings provide the rationale to test the efficacy of SAHA/bortezomib in the treatment of Wp-restricted BL and primary EBV-driven lymphoproliferative diseases, such as PTLD.
Materials and methods

Cell culture
Akata 31 (Ak31) is an EBV-negative BL cell line. Akata 2003 (Ak2003), Mutu-I, Daudi, P3HR1-c16, Raji and Mutu-III are EBV-positive BL cell lines (obtained from Prof. M. Allday and Prof. P. Farrell, Imperial College, London, UK). LCL330, LCL337 and LCL354 were established by immortalization of peripheral blood mononuclear cells (PBMCs) of paediatric PTLD patients with B95-8 strain of EBV. All of the cell lines were cultured in RPMI-1640 medium and supplemented with fetal bovine serum (FBS; 10% and 15% for BL cell lines and LCLs, respectively), 1% penicillin and streptomycin (Invitrogen, Carlsbad, CA, USA) and were grown in a humidified incubator at 37°C with 5% CO 2 .
Chemicals
MS-275, apicidin, panobinostat, sodium butyrate and bortezomib were purchased from Selleck (Selleck Chemicals, Houston, TX, USA). SAHA was purchased from Cayman (Cayman Chemicals, Ann Arbor, MI, USA). N-acetyl-cysteine (NAC) was purchased from Sigma (Sigma-Aldrich, St. Louis, MO, USA).
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay BL and LCLs (5 9 10 5 cells/ml) were seeded in triplicates in 96-well plates and treated with various concentrations of drugs for 24, 48 and 72 h. MTT (Invitrogen) assay was performed and the percentage of cell proliferation was calculated as previously described (Hui & Chiang, 2010; Hui et al, 2012) . Three independent experiments were performed for each MTT assay.
Annexin V/propidium iodide (AV/PI) assay
Burkitt lymphoma and LCLs (5 9 10 5 cells/ml) were treated with SAHA and bortezomib for 48 h. The treated cells were stained with fluorescein isothiocyanate-annexin V (FITC-AV) and propidium iodide (PI; BD PharmingenTM, Heidelberg, Germany) and the percentage of AV/PI-positive cells was calculated as previously described (Hui et al, 2012 (Hui et al, , 2013 . Two independent experiments were performed for each cell line.
Cell cycle analysis
Burkitt lymphoma cells or LCLs (5 9 10 5 cells/ml) were treated with SAHA and bortezomib for 12, 24 and 48 h. The treated cells were subjected to cellular DNA content analysis by flow cytometry as previously described (Hui & Chiang, 2010) . Three independent experiments were performed for each cell line.
Western blot analysis
Burkitt lymphoma cells or LCLs (5 9 10 5 cells/ml) were treated with various concentrations of drugs for 24, 48 and 72 h. Protein from the cell cultures was extracted and Western blot analysis was performed as previously described (Hui & Chiang, 2010) . EBV lytic proteins (Zta), acetylated histone (acetyl-H3), apoptotic proteins [PARP1 (PARP) and cleaved CASP3 (caspase-3)] and TUBA1 (a-tubulin) were detected with the antibodies described previously (Hui et al, 2012) . 
Nude mice experiment
Female BALB/c nude (nu/nu) mice were purchased at 5-6 weeks of age from the Laboratory Animal Unit (LAU), The University of Hong Kong. The mice were housed in the LAU under pathogen-free conditions. All experiments were performed in accordance with the LAU guidelines and approved by the Committee on the Use of Live Animals in Teaching and Research (CULATR) of The University of Hong Kong. P3HR1-c16 (1 9 10 7 ) cells were re-suspended in 200 ll serum-free culture medium. The cells were subcutaneously injected into the right flanks of female BALB/c nude (nu/nu) mice at 6-7 weeks of age. When the tumours became palpable, 60 lg/kg bortezomib, 50 mg/kg SAHA, alone or in combination, was dissolved in DMSO in 10 ll and administered to nude mice of the treatment group (n = 5) by intraperitoneal (IP) injection 5 d per week for 4 weeks. An equal volume of DMSO was administered by injection to nude mice of the control group (n = 5). The size and the weight of the tumours were measured as described previously (Hui et al, 2012 (Hui et al, , 2013 .
Statistical analysis
Synergism of SAHA and bortezomib was analysed with isobologram analysis and combination index (CI) calculation as described previously (Hui et al, 2013; Hui & Chiang, 2014) . Curves that lie under the additive isobole in isobologram suggest synergism and vice versa. CI<1, =1 and >1 represent synergy, additivity and antagonism, respectively. All statistical analyses were performed with GRAPHPAD PRISM Version 5.0 software (Graphpad Software Inc., La Jolla, CA, USA). P values <0Á05 were considered statistically significant. Fig 1A) . According to the data, all these HDAC inhibitors could suppress the proliferation of BL cells in a dose-and time-dependent manner. Half maximal inhibitory concentration (IC50) values of the five HDAC inhibitors on the proliferation of BL cells at 48-h time point were determined ( Table I ). The IC50 values of HDAC inhibitors on BL cells of Wp-restricted (Daudi and P3HR1-c16) and type III (Raji and Mutu-III) latencies were higher than those of latency I (AK2003 and Mutu-I), suggesting that BL cells of Wp-restricted and type III latencies were more resistant to the treatment with HDAC inhibitors. As HDAC inhibitors were shown to induce EBV lytic cycle in BL cells (Ghosh et al, 2012) , we also investigated whether the enhanced resistance to treatment with HDAC inhibitors was related to the refractoriness of EBV lytic cycle induction in the Wprestricted and latency III BL cells (only the results for SAHA were shown because all of the HDAC inhibitors tested showed similar lytic cycle induction; Fig 1B) . HDAC inhibitors could not induce the expression of Zta in almost all these BL cell lines (except weak induction was observed in P3HR1-c16) regardless of the forms of viral latency, indicating that the differential responses of the BL cell lines to killing by HDAC inhibitors were unrelated to EBV lytic cycle induction. Collectively, our data showed that Wp-restricted and latency III BL cells were more resistant to the treatment with HDAC inhibitors when compared with latency I BL cells and the drug resistance was independent of EBV lytic cycle induction.
Results
BL cells of
Combination of SAHA/bortezomib induced synergistic killing of Wp-restricted and latency III BL cells
Given that the combination of SAHA and bortezomib, a proteasome inhibitor, can synergistically induce cell death in (Fig 2A) . When compared with either drug alone, SAHA/bortezomib yielded a much stronger anti-proliferative effect in the Wprestricted and latency III BL cells. However, such enhanced killing could not be observed in the latency I BL cells. Isobologram analysis was performed to determine the synergism between SAHA/bortezomib ( Fig 2B) . Whilst the isoboles lay to the left of the additive isoboles for the Wprestricted and latency III BL cells, they lay to the right for the latency I BL cells, indicating synergism of SAHA/bortezomib in the BL cells of Wp-restricted or type III latency. The synergistic anti-proliferative effect of bortezomib and other HDAC inhibitors (including MS-275, apicidin, panobinostat and NaB) was also observed in the Wp-restricted P3HR1-c16 cells ( Figure S1 ).
Synergistic killing by SAHA/bortezomib could also be achieved in LCLs
To test whether the synergistic killing could also be observed in other EBV-associated B cell lines, we established a panel of EBV-transformed lymphoblastoid cell lines (LCLs), including LCL330, LCL337 and LCL354, from PBMCs of PTLD patients. According to the MTT assay and isobologram analysis, SAHA/bortezomib could also induce killing of all three LCLs synergistically ( Fig 3A) . (Fig 3B) .
SAHA/bortezomib induced apoptosis of Wp-restricted BL cells and latency III LCLs
We postulated that SAHA/bortezomib could antagonize the function of EBNA-3 proteins and induce cell cycle arrest and apoptosis of Wp-restricted BL cells and LCLs. P3HR1-c16 and LCL337 cells were treated with SAHA/bortezomib for 12, 24, 48 and 72 h, stained with PI and subjected to flow cytometric analysis of the cell cycle (Fig 4A and C) . The data at 72 h were not suitable for cell cycle analysis because the majority of the cells underwent apoptosis following drug treatment. Following treatment of P3HR1-c16 cells with the drugs for 24 h, SAHA clearly arrested cell cycle at G1 phase whereas both bortezomib and SAHA/bortezomib arrested similar percentages of cells at G2/M phase. In LCL337, SAHA, bortezomib and SAHA/bortezomib arrested similar percentages of cells at G1 phase. These data indicated no apparent additive or synergistic effect between SAHA and bortezomib on cell cycle arrest in both P3HR1-c16 and LCL337. We also analysed the percentages of the sub-G1 populations, which represent the cells undergoing apoptosis (Fig 4B, D) . The percentages of sub-G1 populations increased over time, from 12 h to 72 h, in the cells treated with SAHA/bortezomib or either drug alone. At 48-h, significantly higher percentages of sub-G1 populations was observed in the cells treated with SAHA/bortezomib (c. 37% and c. 53% in P3HR1-c16 and LCL337, respectively) when compared with those treated with either drug alone. We confirmed the enhanced apoptosis by AV/PI staining (Fig 4E) . Following 48 h of treatment with SAHA, bortezomib or SAHA/bortezomib, the percentages of apoptotic cells (AV+) increased to 17Á1%, 20Á0% and 58Á5% in P3HR1-c16 and to 13Á7%, 39Á7% and 86Á6% in LCL337, respectively. To further analyse the relationship between the cell cycle arrest and apoptosis, we performed time course experiments to investigate the kinetics of expression of several cell cycle and apoptotic markers following treatment with SAHA/bortezomib (Fig 4F) . Expression of apoptotic markers (cleaved PARP1 and CASP3) appeared at 4 h and 8 h in LCL337 and I  0Á37  90Á79  4Á51  0Á55  0Á49  Mutu-I  I  0Á70  78Á48  4Á65  0Á26  0Á40  Daudi  Wp  0Á80  501Á70  17Á28  1Á72  1Á56  P3HR1-c16  Wp  11Á29  684Á3  3 3 Á47  1Á84  5Á57  Raji  III  5Á61  1220Á00  33Á28  1Á31  10Á57  Mutu-III  III  3Á90  971Á70  75Á71  3Á73  7Á74 P3HR1-c16, respectively. However, there was no significant alteration in the protein levels of the cell cycle regulators [CCND1 (cyclin-D1), CDK4, CCNB1 (cyclin-B1) and phosphorylated (p-)CDK1 (p-cdc2)] in both cell lines up to 24 h, when down-regulation of CDK4, CCNB1 and p-CDK1 was observed. The early activation of apoptotic markers in the cell lines suggested the existence of two cellular subpopulations in response to the treatment with SAHA/bortezomib, SAHA/bortezomib induced the expression of CDKN2A and CDKN1A, concomitant with the up-regulation of apoptotic markers
Tumour suppressor proteins, including BCL2L11, CDKN2A and CDKN1A, were shown to be down-regulated by EBNA-3 proteins, hence facilitating the growth of EBV-associated malignancies (Cooper et al, 2003; Maruo et al, 2006 Maruo et al, , 2011 Anderton et al, 2008; Hertle et al, 2009; Paschos et al, 2009; Saha et al, 2011) . We investigated whether SAHA/bortezomib could increase the levels of these tumour suppressor proteins in Wp-restricted BL and LCLs. P3HR1-c16 cells and LCL337 were treated with combination of SAHA/bortezomib for 24 h and the cell lysates of the treated cells were analysed for expression of tumour suppressor proteins [CDKN2A, CDKN1A, CDKN1B (p27) and BCL2L11], apoptotic markers (PARP1, cleaved PARP1 and cleaved CASP3) and cell cycle regulatory proteins (CCND1, CDK4, CCNB1 and p-CDK1) by Western blotting (Fig 5) . When compared with either drug alone, SAHA/bortezomib significantly induced the expression of CDKN2A and CDKN1A but not CDKN1B (Fig 5A) or BCL2L11 (Fig 5B) in both P3HR1-c16 and LCL337 cells. Concomitantly, SAHA/bortezomib increased the expression of cleaved PARP1 and cleaved CASP3 and decreased the expression of PARP1, CDK4, CCNB1 and p-CDK1. The up-regulation of the apoptotic markers and down-regulation of cell cycle markers were consistent with the data presented in Fig 4F. Together, the data indicated that induction of apoptosis and down-regulation of cell cycle regulatory proteins mediated by SAHA/bortezomib might be related to the up-regulation of CDKN2A and CDKN1A.
Up-regulation of CDKN2A and CDKN1A and induction of apoptosis were dependent on the generation of reactive oxygen species (ROS)
We and others have reported that SAHA/bortezomib could synergistically induce apoptosis of various types of cancer cells through an ROS-dependent mechanism (Yu et al, 2003; Denlinger et al, 2004; Pei et al, 2004; Heider et al, 2008 Heider et al, , 2009 Hui et al, 2013) . We postulated that SAHA/bortezomib could mediate a similar apoptotic mechanism in both Wp-restricted BL and LCLs. We pre-treated P3HR1-c16 and LCL337 with 12 mmol/l N-acetyl cysteine (NAC), an ROS scavenger, for 1 h before treatment with SAHA/bortezomib. Addition of NAC significantly reduced the cleavage of PARP1 and CASP3 in both P3HR1-c16 and LCL337 (Fig 5C) . Interestingly, NAC also significantly reduced the protein levels of CDKN2A and CDKN1A (Fig 5D and Figure  S2 ). Taken together, the data showed that SAHA/bortezomib could induce the up-regulation of CDKN2A and CDKN1A and apoptosis in Wp-restricted BL and LCLs via an ROSdependent mechanism (Fig 5E) .
SAHA/bortezomib significantly suppressed the growth of Wp-restricted BL xenografts in nude mice
Finally, we attempted to examine the in vivo effect of SAHA/ bortezomib on growth suppression of Wp-restricted BL and LCL xenografts. However, only the xenografts of P3HR1-c16, but not LCLs, grew in nude mice. The mice bearing the P3HR1-c16 xenografts were treated with either DMSO (vehicle control) (n = 5), 50 mg/kg SAHA (n = 5), 60 lg/kg bortezomib (n = 5) or combination of 50 mg/kg SAHA and 60 lg/kg bortezomib (n = 5) for 5 d per week over 15 d by IP injection (Fig 6A) . Toxicity of SAHA, bortezomib or their combination in nude mice was assessed by monitoring their weight (Fig 6B) . Despite weight loss of approximately 5%, no other noticeable toxicity was observed in the mice treated with SAHA/bortezomib or either drug alone. The growth of tumours was measured during the experimental period (Fig 6C) . On day 6 post-treatment, mean tumour volumes of mice treated with vehicle control, SAHA or bortezomib started to exceed that of the group treated by SAHA/bortezomib. At the end of experiment (day 15 post-treatment), the mean tumour volumes of mice treated with vehicle control, SAHA, bortezomib and SAHA/bortezomib were 4093 mm 3 , 2950 mm 3 , 2948 mm 3 , and 1048 mm 3 , respectively. Whilst either SAHA or bortezomib alone suppressed the growth of tumours, their combination mediated a much stronger suppressive effect (P < 0Á01) (Fig. 6d) .
Discussion
Epstein-Barr virus latent proteins exert anti-apoptotic effects on Wp-restricted BL and LCLs through down-regulation of BCL2L11, CDKN2A and CDKN1A (Cooper et al, 2003; Maruo et al, 2006 Maruo et al, , 2011 Anderton et al, 2008; Hertle et al, 2009; Paschos et al, 2009; White et al, 2010; Saha et al, 2011) . HDAC inhibitors can synergize with proteasome inhibitors to up-regulate these tumour suppressor genes (Yu et al, 2003; Pei et al, 2004; Emanuele et al, 2007; Heider et al, 2009; Hui & Chiang, 2014) . In this study, we hypothesized that combination of HDAC and proteasome inhibitors could synergistically induce apoptosis of Wp-restricted BL and LCL. We first tested the responses of six endemic BL cell lines, which expressed either type I, Wp-restricted or type III latency, to a panel of HDAC inhibitors. We found that both Wp-restricted and latency III BL cell lines displayed higher resistance to killing by HDAC inhibitors when compared to latency I BL cell lines (to Fig 1, Table I ). Despite the identical cellular background of Mutu-I (latency I) and Mutu-III (latency III) cell lines (Gregory et al, 1990) , Mutu-III cells were more resistant to HDAC inhibitor-mediated killing when compared with Mutu-I cells, strongly implicating the involvement of EBV latent proteins in the mechanism of (Rickinson & Kieff, 2007) . We speculated that EBNA-3A and -3C might contribute to the resistance of Wp-restricted BL cells to the The results were analysed for statistical significance using One-way ANOVA Dunnett's Multiple Comparison Test. P -value <0Á05 was considered statistically significant; *P < 0Á05, **P < 0Á01, and ***P < 0Á001 compared with SAHA/bortezomib. Error bars represent the standard error of mean (SEM) of data obtained in at least three independent experiments. (E) Annexin V/propidium iodide (AV/PI) staining was performed to analyse for the percentages of apoptotic cells upon treatment with SAHA/bortezomib or either drug alone for 48 h. AV+/PIÀ population represents early apoptotic cells whilst AV+/PI+ population represents late apoptotic/necrotic cells. (F) P3HR1-c16 and LCL337 were treated with combination of SAHA (2 lmol/l and 1 lmol/l for P3HR1-c16 and LCL337, respectively) and bortezomib (8 nmol/l) for 0, 2, 4, 8, 12 and 24 h. The cellular proteins were extracted and analysed for expression of PARP1, cleaved PARP1, cleaved CASP3, CCND1, CDK4, CCNB1 and p-CDK1 by Western blot analysis. TUBA1 was detected as a loading control.
killing effect of HDAC inhibitors (Anderton et al, 2008; Skalska et al, 2010) . As HDAC inhibitors were reported to induce EBV lytic cycle in BL cell lines, we also analysed whether the expression of EBV lytic proteins might be involved in the drug resistance of Wp-restricted or latency III BL cells (Rodriguez et al, 1999; Jung et al, 2007; Iwamoto et al, 2011) . We found that HDAC inhibitors could only induce low expression levels of EBV lytic proteins in P3HR1-c16 cells, but not in other BL cell lines (Fig 1) . Indeed, we had shown that HDAC inhibitors preferentially induce EBV lytic cycle in EBV-positive epithelial rather than B-cell malignancies (Hui & Chiang, 2010; Hui et al, 2012) . The data implied that the mechanism of drug resistance of Wp-restricted or latency III BL cells was independent of EBV lytic cycle induction. Our laboratory and others had previously reported that proteasome inhibitors, such as bortezomib, could potentiate the anti-tumour effect of HDAC inhibitors, such as SAHA, in various types of cancers (Emanuele et al, 2007; Miller et al, 2009; Zhang et al, 2009; Hui et al, 2013) . Moreover, combination of HDAC and proteasome inhibitors can up-regulate tumour suppressor genes in different cancer cell lines (Yu et al, 2003; Pei et al, 2004; Emanuele et al, 2007; Heider et al, 2009; Hui & Chiang, 2014) . Here, we demonstrated that SAHA/bortezomib could synergistically induce killing of Wp-restricted (Daudi and P3HR1-c16) or latency III (Raji and Mutu-III) BL cells but not latency I BL lines (Ak2003 and Mutu-I). Interestingly, the drug combination could also induce synergistic killing of EBV-transformed LCLs, which also express type III latency. The synergistic killing was due to apoptosis, as evidenced by the higher percentage of annexin V-positive and sub-G1 populations and stronger cleavage of PARP1 and CASP3.
EBNA-3 proteins could provide anti-apoptotic effect through down-regulation of tumour suppressor genes, including BCL2L11, CDKN2A and CDKN1A (Cooper et al, 2003; Maruo et al, 2006 Maruo et al, , 2011 Anderton et al, 2008; Hertle et al, 2009; Paschos et al, 2009; White et al, 2010; Saha et al, 2011 ). We analysed the expression level of BCL2L11, CDKN2A and CDKN1A and the viral encoded Bcl2 homologue, BHRF1, upon treatment with SAHA/bortezomib and found that the drug combination could significantly up-regulate the expression of CDKN2A and CDKN1A, but not BCL2L11 nor BHRF1. One potential pro-apoptotic effect of CDKN2A and CDKN1A was mediated by arresting cells at G1 or G2/M phases (Davis et al, 1998; Park et al, 2002; Mandl-Weber et al, 2010; Wang et al, 2010) . We did not observe this casual relationship between cell cycle arrest and enhanced apoptosis in both Wp-restricted BL and LCLs upon treatment with SAHA/bortezomib, which seemed to briskly induce apoptosis of Wp-restricted BL and LCLs without arrest of the cell cycle. Indeed, CDKN2A has been shown to preferentially induce apoptosis in proliferating cells rather than G1-arrested cells (Minami et al, 2003; Al-Mohanna et al, 2004) . CDKN1A can also directly promote apoptosis in different cancer cell lines through mechanisms involving the activation of TNF receptors or induction of pro-apoptotic protein, BAX (Abbas & Dutta, 2009 ). In addition, the induction of apoptosis and up-regulation of CDKN2A and CDKN1A by SAHA/bortezomib were ROS-dependent, which is consistent with previous findings that ROS generation induced the expression of CDKN2A and CDKN1A and triggered apoptosis of different cancer cell lines (Donadelli et al, 2006; Kim & Wong, 2009; Luo et al, 2011; Hui et al, 2013; Hui & Chiang, 2014) . We further evaluated the effect of SAHA/bortezomib on Wprestricted BL xenografts in nude mice and found that the drug combination significantly suppressed the growth of Wprestricted BL xenografts in nude mice, indicating that the in vitro anti-tumour effect of SAHA/bortezomib could also be achieved in vivo. Collectively, our results proposed a novel synergistic action of SAHA/bortezomib in Wp-restricted BL and LCLs through the up-regulation of CDKN2A and CDKN1A, in a ROS-dependent pathway and possibly reversing the suppressive effect of EBNA-3 proteins on these tumour suppressor proteins. The potential application of this drug regimen as an alternative clinical regimen for the treatment of Wp-restricted BL and PTLD should be further investigated.
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